Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqaf044 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Carol N Rizkalla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States. Hauptthemen laut MEDLINE: Osteoclasts, Giant Cells, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
Osteoclast-rich undifferentiated carcinoma of the urinary tract, herein referred to as urothelial carcinoma with osteoclast-like giant cells (UCOGC), is a rare tumor currently classified under the “poorly differentiated urothelial carcinoma” subtype. This study aimed to evaluate the clinicopathologic, immunophenotypic, and molecular features of UCOGC to better characterize its origin and support its classification as a unique subtype.
Methods
There were 14 UCOGCs studied with immunohistochemistry/in situ hybridization and compared to urothelial carcinomas with trophoblastic differentiation (n = 6) and giant cell urothelial carcinomas (n = 5). Markers were assessed in mononuclear (MN) and giant cell (GC) components. Next-generation sequencing was performed on 4 UCOGCs.
Results
The MN cells of UCOGC demonstrated high expression of CD68, CD163, SATB2, cathepsin K, and CSF1 in situ hybridization (ISH), with moderate staining for GATA3, p63, and PU.1 and low staining for pankeratin. The GCs showed high CD68, PU.1, and cathepsin K expression but low CD163, SATB2, and CSF1 ISH, with no staining for urothelial markers or pankeratin. Both MN and GC were negative for H3.G34W and HCG. Next-generation sequencing revealed mutations consistent with conventional urothelial carcinomas.
Conclusions
The distinct biphasic morphology, characteristic immunophenotype, and molecular findings of UCOGC suggest it is of urothelial origin, and we believe it justifies its classification as a unique subtype rather than under “poorly differentiated urothelial carcinoma.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
- Department of Pathology, Stanford Medical Center, Stanford, CA, United States.
- Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
- Henry Ford Hospital, Detroit, MI, United States.
- Department of Pathology, Indiana University, Indianapolis, IN, United States.
- University of Colorado, Department of Pathology, Aurora, CO, United States.
ORCID-Profile: Sean R Williamson, Khaleel I Al-Obaidy, Susan Potterveld
Zitieren
APA
Rizkalla, C. N., Tretiakova, M., Suarez, C. J., Williamson, S. R., Al-Obaidy, K. I., Acosta, A. M., Idrees, M. T., Chan, E., Potterveld, S., & Sangoi, A. R. (2025). Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf044
Vancouver
Rizkalla CN, Tretiakova M, Suarez CJ, Williamson SR, Al-Obaidy KI, Acosta AM, et al. Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf044
BibTeX
@article{Rizkalla2025,
author = {Rizkalla, Carol N and Tretiakova, Maria and Suarez, Carlos J and Williamson, Sean R and Al-Obaidy, Khaleel I and Acosta, Andres M and Idrees, Muhammad T and Chan, Emily and Potterveld, Susan and Sangoi, Ankur R},
title = {Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqaf044}
}
EUVIMED